H2S IN DIABETES

Preclinical efficacy testing of hydrogen sulfide donors against diabetic complications

Coordinatore	THE UNIVERSITY OF EXETER    more  Organization address address: Northcote House, The Queen's Drive city: EXETER postcode: EX4 4QJ contact info Titolo: Ms. Nome: Gaynor Cognome: Hughes Email: send email Telefono: +44 1392 725835 Fax: +44 1392 723686
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	309˙235 €
EC contributo	309˙235 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-IEF
Funding Scheme	MC-IEF
Anno di inizio	2015
Periodo (anno-mese-giorno)	2015-02-01   -   2017-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE UNIVERSITY OF EXETER  Organization address address: Northcote House, The Queen's Drive city: EXETER postcode: EX4 4QJ contact info Titolo: Ms. Nome: Gaynor Cognome: Hughes Email: send email Telefono: +44 1392 725835 Fax: +44 1392 723686	UK (EXETER)	coordinator	309˙235.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Diabetic complications are the leading cause of morbidity and mortality in diabetic patients. Oxidative stress and inflammation contributes to the loss of endothelial function and dysfunction of the vascular endothelium plays a major role in diabetic macrovascular and microvascular complications. We found that hydrogen sulfide can reduce the hyperglycemia-induced mitochondrial reactive oxygen species (ROS) production in endothelial cells and can prevent diabetic vascular dysfunction in aortic rings. However, it has not been possible to test the protective effect of hydrogen sulfide against long-term diabetic complications because of its short half-life. Novel slow-release hydrogen sulfide donors were generated that allow long-term hydrogen sulfide treatment. We now propose to test the protective effect of slow-release hydrogen sulfide donors against glucose-induced ROS generation and the development of diabetic long-term complications. We aim (1) to identify the most potent hydrogen sulfide donor compounds against hyperglycemia-induced ROS generation in endothelial cells (2) to test the efficacy of the lead compounds in human microvessels and (3) determine the efficacy of the most potent drug candidates against diabetic nephropathy in streptozotocin-induced diabetes (Type 1 diabetes model) and in db/db mice (Type 2 diabetes model). The mechanism of action of hydrogen sulfide against mitochondrial ROS generation suggests that slow-release hydrogen sulfide donors may be applicable against diabetic complications in humans. We expect that the proposed preclinical efficacy studies will initiate rapid clinical translation and these promising drugs will be used in human diabetic complications.'